The tiny magnetic particles of the Magtrace® lymphatic tracer are optimised to take the same path a spreading cancer cell would through the lymphatic system, making it an ideal tracer for sentinel lymph node biopsy procedures.
The Magtrace® lymphatic tracer is a liquid tracer that has been developed specifically for sentinel node biopsies. Detected by our Sentimag® localisation system, this non-radioactive tracer directs surgeons to the first draining lymph nodes most likely to contain cancer to help determine if it has spread.
This simple liquid allows any patient or any hospital to access the highest standard in breast cancer staging.
Just one injection required, compared to radioisotope and blue dye.
Can be injected up to 7 days or as little as 20 minutes before surgery.
The tiny particles are optimised for nodes, providing a clear signal and visual when performing sentinel node biopsy procedures.
Can be injected 20 minutes before surgery while patient is anaesthetised.
No unpleasant sensations or risk of anaphylaxis like blue dye.†
No radiation exposure or limitations on supply and storage.
...a real game-changer in the way we treat breast cancer in the United States.